company background image
DXB logo

Dimerix ASX:DXB Stock Report

Last Price

AU$0.58

Market Cap

AU$332.6m

7D

7.4%

1Y

900.0%

Updated

13 Jun, 2024

Data

Company Financials

DXB Stock Overview

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs.

DXB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Dimerix Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dimerix
Historical stock prices
Current Share PriceAU$0.58
52 Week HighAU$0.61
52 Week LowAU$0.055
Beta0.56
1 Month Change70.59%
3 Month Change78.46%
1 Year Change900.00%
3 Year Change157.78%
5 Year Change673.33%
Change since IPO190.00%

Recent News & Updates

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dec 19
Is Dimerix (ASX:DXB) Using Too Much Debt?

Recent updates

Is Dimerix (ASX:DXB) Using Too Much Debt?

Dec 19
Is Dimerix (ASX:DXB) Using Too Much Debt?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Jul 05
We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Can Dimerix (ASX:DXB) Afford To Invest In Growth?

Feb 17
Can Dimerix (ASX:DXB) Afford To Invest In Growth?

We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

Sep 16
We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate

We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Jun 02
We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate

Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Sep 20
Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation

Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

May 17
Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?

Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Feb 01
Here's What We Think About Dimerix's (ASX:DXB) CEO Pay

Shareholder Returns

DXBAU BiotechsAU Market
7D7.4%-1.5%-0.7%
1Y900.0%-0.5%8.2%

Return vs Industry: DXB exceeded the Australian Biotechs industry which returned -0.5% over the past year.

Return vs Market: DXB exceeded the Australian Market which returned 8.2% over the past year.

Price Volatility

Is DXB's price volatile compared to industry and market?
DXB volatility
DXB Average Weekly Movement12.9%
Biotechs Industry Average Movement11.4%
Market Average Movement8.7%
10% most volatile stocks in AU Market16.5%
10% least volatile stocks in AU Market3.2%

Stable Share Price: DXB's share price has been volatile over the past 3 months.

Volatility Over Time: DXB's weekly volatility has decreased from 26% to 13% over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
n/an/aNina Websterdimerix.com

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.

Dimerix Limited Fundamentals Summary

How do Dimerix's earnings and revenue compare to its market cap?
DXB fundamental statistics
Market capAU$332.57m
Earnings (TTM)-AU$10.87m
Revenue (TTM)AU$9.12m

35.0x

P/S Ratio

-29.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DXB income statement (TTM)
RevenueAU$9.12m
Cost of RevenueAU$0
Gross ProfitAU$9.12m
Other ExpensesAU$19.98m
Earnings-AU$10.87m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.02
Gross Margin100.00%
Net Profit Margin-119.20%
Debt/Equity Ratio83.2%

How did DXB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.